 Safety and tolerability of Indoximod will also be evaluated at the RP2D in combination with standard-of-care SOC chemotherapy defined as induction therapy with idarubicin and cytarabine and consolidation with high-dose cytarabine HiDAC in this trial followed by single agent indoximod maintenance therapy in patients with newly diagnosed AML as compared to safety and tolerability of SOC chemotherapy alone. 